Steroid immunosuppression in kidney transplantation: A passing era

Journal of Surgical Research

Volumn 117, Issue 1, 2004, Pages 154-162

  Schulak, James A ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CYCLOSPORIN; FLUINDOSTATIN; IMMUNOSUPPRESSIVE AGENT; INSULIN; LYMPHOBLAST ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; ORAL ANTIDIABETIC AGENT; PREDNISONE; RAPAMYCIN; STEROID; T LYMPHOCYTE ANTIBODY; TACROLIMUS; THYMOCYTE ANTIBODY;

B LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CYTOTOXICITY; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; ETHNOLOGY; GENE INDUCTION; GRAFT REJECTION; GRAFT SURVIVAL; HELPER CELL; HUMAN; HUMORAL IMMUNITY; HYPERLIPIDEMIA; HYPERTENSION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; LEUKOCYTOSIS; LEUKOPENIA; LIPID METABOLISM; LOW DRUG DOSE; METABOLIC DISORDER; ORGAN DONOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; STATISTICAL ANALYSIS; WOUND HEALING IMPAIRMENT;

EID: 1542268356     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jss.2003.11.005     Document Type: Article

References (51)

1. Starzl T.E., Marchioro T.L., Waddel W.R. The reversal of rejection in human renal homografts with subsequent development of homograft tolerance. Surg. Gynecol. Obstet. 117:1963;385.
2. David D.S., Grieco M.H., Cushman P. Adrenal corticosteroids after twenty years a review of their clinical relevant consequences. J. Chron. Dis. 22:1970;637.
3. Kjellstrand C.M. Side effects of steroids and there treatment. Transplant. Proc. 7:1975;123.
4. Woods J.E., Anderson C.F., DeWeerd J.H., Johnson W.J., Donadio J.V. Jr, Leary F.J., Frohnert P.P. High-dose intravenously administered methylprednisolone in renal transplantation. A preliminary report. JAMA. 223:1973;896.
5. Fauci A.S. The effect of hydrocortisone on the kinetics of normal human lymphocytes. Blood. 46:1975;235.
6. Almawi W.Y., Hadro E.T., Strom T.B. Evidence that glucocorticosteroid- mediated immunosuppressive effects do not involve altering second messenger function. Transplantation. 52:1991;133.
7. Vacca A., Felli M.P., Farina A.R., Martinotti A., Maroder M., Screpanti I., Meco D., Petrangeli E., Frati L., Gulino A. Glucorticoid receptor-mediated suppression of the interleukin-2 gene expression through impairmant of the sooperativity between nuclear factor of activated T cells and AP-1 enhancer elements. J. Exp. Med. 175:1992;637.
8. Barnes P.J., Adcock I. Anti-inflammatory actions of steroids molecular mechanisms. Trends Pharmacol. Sci. 14:1993;436.
9. Scheinman R.I., Gualberto A., Jewell C.M., Cidlowski J.A., Baldwin A.S. Characterization of mechanisms involved in transrepression of NF-kB by activated glucocorticoid receptors. Mol. Cell. Biol. 15:1995;943.
10. Knudsen P.J., Dinarello C.A., Strom T.B. Glucocorticoids inhibit transplantational and post-transcriptional expression of interleukin-1 in U937 cells. J. Immunol. 139:1987;4129.
11. Zanker B., Walz G., Wieder K.J., Strom T.B. Evidence that glucocorticoids block expression of the human interleukin-6 gene by accessory cells. Transplantation. 49:1990;183.
12. Waage A., Bakke O. Glucocorticoids suppress the production of tumor necrosis factor by lipopolysaccharide-stimulated human monocytes. Immunology. 63:1988;299.
13. Vacca A., Martinotti S., Screpanti I., Maroder M., Felli M.P., Farina A.R., Gismondi A., Santoni A., Frati L., Gulino A. Transcriptional regulation of the interleukin-2 gene by glucocorticoid hormones. J. Biol. Chem. 265:1990;8075.
14. Arya S.K., Wong-Staal F., Gallo R.C. Dexamethosone-mediated inhibition of human T cell growth factor and γ-interferon messenger RNA. J. Immunol. 133:1984;273.
15. European Multicentre Trial. Cyclosporine A as a sole immunosuppressive agent in recipients of kidney allografts from cadaver donors. Lancet. 2:1982;57.
16. Calne R.Y. Cyclosporine in cadaveric renal transplantation 5-year follow-up of a multicentre trial. Lancet. 2:1987;506.
17. Gruber S.A., Chan G.L.C., Canafax D.M., Matas A.J. Immunosuppression in renal transplantation I. Cyclosporine and azathioprine. Clin. Transplant. 5:1991;65.
18. Squifflet J., Sutherland D.E.R., Rynasiewicz J.J., Field J., Heil J., Najarian J.S. Combined immunosuppression therapy with cyclosporine A and azathioprine. Transplantation. 34:1982;315.
19. Bry W., Warvariv V., Bohannon L., Feduska N., Straube G., Levin B. Cadaveric renal transplantation without prophylactic prednisone therapy. Transplant. Proc. 23:1991;994.
20. Knechtle S.J., Pirsch J.D., Fechner J.H., Becker B.N., Friedl A., Colvin R.B., LeBeck L.K., Chin L.T., Becker Y.T., Odorico J.S., D'Alessandro A.M., Kalayoglu M., Hamawy M.M., Huaizhong H., Bloom D.D., Sollinger H.W. Campath-1H induction plus rapamycin monotherapy for renal transplantation results of a pilot study. Am. J. Transplant. 3:2003;722.
21. Starzl T.E., Murase N., Abu-Elmagd K., Gray E.A., Shapiro R., Corry R.J., Jordan M.L., Fontes P., Gayowski T., Bond G., Scantlebury B.P., Potdar S., Randhawa P., Wu T., Zeevi A., Nalesnik M.A., Marcos A., Trucco M., Demetris A.J., Fung J.J. Tolerogenic immunosuppression for organ transplantation. Lancet. 361:2003;1502.
22. Stratta R.J., Armbrust M.J., Oh C.S., Pirsch J.D., Kalayoglu M., Sollinger H.W., Belzer F.O. Withdrawal of steroid immunosuppression in renal transplant recipients. Transplantation. 45:1988;323.
23. Matas A.J., Ramcharan T., Paraskevas S., Gillingham K.J., Dunn D.L., Gruessner R.W.G., Humar A., Kandaswamy R., Najarian J.S., Payne W.D., Sutherland D.E.R. Rapid discontinuation of steroids in living donor kidney transplantation a pilot study. Am. J. Transplant. 1:2001;278.
24. Stegall M.D., Wachs M., Everson G.T., Kam I. Corticosteroid withdrawal in solid organ transplantation. Transplant. Rev. 12:1998;140.
25. Hricik D.E. Steroid-free immunosuppression in kidney transplantation an editorial review. Am. J. Transplant. 2:2002;19.
26. Schulak J.A., Hricik D.E. Steroid withdrawal after renal transplantation. Clin. Transplant. 8:1994;211.
27. Schulak J.A., Mayes J.T., Moritz C.E., Hricik D.E. A prospective randomized trial of prednisone versus no prednisone maintenance therapy in cyclosporine-treated and azathioprine-treated renal transplant patients. Transplantation. 49:1990;327.
28. Hricik D.E., Whalen C.C., Lautman J., Bartucci M.R., Moir E.J., Mayes J.T., Schulak J.A. Withdrawal of steroids after renal transplantation clinical predictors of outcome. Transplantation. 53:1992;41.
29. Schulak J.A., Moritz C.E., Hricik D.E. Renal transplantation without prednisone effects on bone marrow tolerance to azathioprine. Transplant. Proc. 21:1989;1709.
30. Hricik D.E., Moritz C.E., Mayes J.T., Schulak J.A. Association of the absence of steroid therapy with increased cyclosporine blood levels in renal transplant recipients. Transplantation. 49:1990;221.
31. Hricik D.E., Bartucci M.R., Moir E.J., Mayes J.T., Schulak J.A. Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation. 51:1991;374.
32. Hricik D.E., Schulak J.A., Sell D.R., Fogarty J.F., Monnier V.M. Effects of kidney or kidney-pancreas transplantation on plasma pentosidine. Kidney Int. 43:1993;398.
33. Hricik D.E., Lautman J., Bartucci M.R., Moir E.J., Mayes J.T., Schulak J.A. Variable effects of steroid withdrawal on blood pressure reduction in cyclosporine-treated renal transplant recipients. Transplantation. 53:1992;1232.
34. Hricik D.E., Mayes J.T., Schulak J.A. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia. Am. J. Kidney Dis. 18:1991;353.
35. Hricik D.E., Bartucci M.R., Mayes J.T., Schulak J.A. The effects of steroid withdrawal on the lipoprotein profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients. Transplantation. 54:1992;868.
36. Austen J.L., Shifrin F.A., Bartucci M.R., Knauss T.C., Schulak J.A., Hricik D.E. Effects of fluvastatin on hyperlipidemia after renal transplantation influence of steroid therapy. Ann. Pharmacother. 30:1996;1386.
37. Hricik D.E., Seliga R.M., Fleming-Brooks S., Bartucci M.R., Schulak J.A. Determinants of long-term allograft function following steroid withdrawal in renal transplant recipients. Clin. Transplant. 9:1995;419.
38. Ghandour F.Z., Knauss T.C., Mulligan D.C., Schulak J.A., Hricik D.E. Influence of steroid withdrawal on proteinuria in renal transplant recipients. Clin. Transplant. 11:1997;395.
39. Hricik D.E., Schulak J.A. Steroid withdrawal from cyclosporine-based regimens a flawed strategy. Transplant. Proc. 30:1998;1785.
40. Steroid Withdrawal Study Group. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil a prospective randomized study. Transplantation. 68:1999;1865.
41. Hricik D.E., Anton H.A.S., Knauss T.C., Rodriguez V., Seaman D., Siegel C., Valente J., Schulak J.A. Outcomes of African-American kidney transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. Transplantation. 74:2002;189.
42. Hricik D.E., Knauss T.C., Bodziak K.A., Weigel K., Rodriguez V., Seaman D., Siegel C., Valente J., Schulak J.A. Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus. Transplantation. 76:2003;938.
43. Valente J.F., Hricik D., Weigel K., Seaman D., Knauss T., Siegel C.T., Bodziak K., Schulak J.A. Comparison of sirolimus v. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am. J. Transplant. 3:2003;1128.
44. Sarwal M.M., Yorgin P.D., Alexander S., Milan M.T., Belson A., Belanger Granucci L., Major C., Costaglio C., Sanchez J., Orlandi P., Salvetierra C. Jr. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation. 72:2001;13.
45. Diem H.V., Sokal E.M., Janssen M., Otte J.B., Reding R. Steroid withdrawal after pediatric liver transplantation a long-term follow-up study in 109 recipients. Transplantation. 75:2003;1664.
46. Pirenne J., Aerts R., Koshiba T., Van Gelder F., Roskams T., Schetz M., Verhaegen M., Lauwers P., Fevery J., Vevens F. Steroid-free immunosuppression during and after liver transplantation a 3-year follow-up report. Clin. Transplant. 17:2003;177.
47. Jordan M.L., Chakrabarti P., Luke P., Shapiro R., Vivas C.A., Scantlebury V.P., Fung J.J., Starzl T.E., Corry R.J. Results of pancreas transplantation after steroid withdrawal under tacrolimus immunosuppression. Transplantation. 69:2000;265.
48. Kaufman D.B., Leventhal J.R., Koffron A.J., Gallon L.G., Parker M.A., Frye J.P., Abecassis M.M., Stuart F.P. A prospective study of rapid corticosteroid elimination in simultaneous pancreas-kidney transplantation: comparison of two maintenance immunosuppression protocols: tacrolimus/ mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation. 73:2002;169.
49. Heeger P.S., Greenspan N.S., Kuhlenschmidt S., Dejelo C., Hricik D.E., Schulak J.A., Tary-Lehmann M. Pretransplant frequency of donor-specific, interferon gamma producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J. Immunol. 163:1999;2267.
50. Vincenti F. What's in the pipeline? New immunosuppressive drugs in transplantation. Am. J. Transplant. 2:2002;898.
51. Auchincloss H. Jr. In search of the elusive Holy Grail The mechanisms and prospects for achieving clinical transplantation tolerance. Am. J. Transplant. 1:2001;6.